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Abstract
Distinct prion strains often exhibit different incubation periods and patterns of neuropathological lesions. Strain
characteristics are generally retained upon intraspecies transmission, but may change on transmission to another species.
We investigated the inactivation of two related prions strains: BSE prions from cattle and mouse-passaged BSE prions,
termed 301V. Inactivation was manipulated by exposure to sodium dodecyl sulfate (SDS), variations in pH, and different
temperatures. Infectivity was measured using transgenic mouse lines that are highly susceptible to either BSE or 301V
prions. Bioassays demonstrated that BSE prions are up to 1,000-fold more resistant to inactivation than 301V prions while
Western immunoblotting showed that short acidic SDS treatments reduced protease-resistant PrP
Sc from BSE prions and
301V prions at similar rates. Our findings argue that despite being derived from BSE prions, mouse 301V prions are not
necessarily a reliable model for cattle BSE prions. Extending these comparisons to human sporadic Creutzfeldt-Jakob disease
and hamster Sc237 prions, we found that BSE prions were 10- and 10
6-fold more resistant to inactivation, respectively. Our
studies contend that any prion inactivation procedures must be validated by bioassay against the prion strain for which
they are intended to be used.
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Introduction
Prions are proteinaceous infectious particles that cause invari-
ably fatal neurodegenerative diseases, including Creutzfeldt-Jakob
disease (CJD) and kuru in humans, bovine spongiform encepha-
lopathy (BSE), chronic wasting disease (CWD) in deer and elk, and
scrapie in sheep and goats. The only known component of the
prion is an alternatively folded isoform, denoted PrP
Sc, of the
prion protein (PrP). The PrP
Sc isoform is derived from the normal,
cellular PrP, denoted PrP
C, through a poorly understood process.
Accumulation of PrP
Sc in the central nervous system results in
spongiform changes and death.
Distinct prions strains often exhibit different incubation periods
and patterns of neuropathological lesions. Strain characteristics
are generally retained upon intraspecies transmission, but may
change on transmission to another species [1–4]. For many years,
the biological properties of prion strains were thought to be
encoded by a nucleic acid [5] but none was found. Data from
numerous studies offer convincing evidence that strain-specified
information is enciphered in the conformation of PrP
Sc [3,6–11].
Among the characteristics that distinguish prion strains is
resistance to inactivation. The extreme resistance of prions was
first noted when numerous sheep immunized against looping-ill
virus developed scrapie. The inoculum had been prepared from
pooled sheep brains, spinal cords, and spleens, treated with
formalin and certified free of viruses [12]. Later, the resistance of
prions to both ionizing and ultraviolet radiation was found
[13,14]. As preparations of Sc237-infected Syrian hamster brain
were progressively enriched for scrapie infectivity, procedures that
modified proteins were found to inactivate the samples, while
those that modified nucleic acids had no effect [15]. The results of
numerous earlier studies concluded that protein denaturants were
effective at reducing infectivity titers [16] but that complete
inactivation required harsh conditions [17,18].
The BSE epidemic and almost 200 cases of variant CJD in the
United Kingdom as well as the growing problem of CWD in the
United States have raised concerns about the spread of prion
infectivity. These diseases highlight the need to decontaminate
effectively meat processing equipment and other instrumentation
of prions. Procedures used for routine sterilization of surgical
instruments do not inactivate prions, which led to the development
of stringent recommendations for reprocessing instruments used
on known or suspected CJD cases [19]. These recommendations
include autoclaving at 121uC in the presence of 1 M sodium
hydroxide, or soaking in 2% sodium hypochlorite for 1 h.
However, these highly corrosive procedures can cause significant
damage to surgical instruments [20,21] and therefore, are rarely
used. Other less stringent procedures, such as autoclaving at
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although it is acknowledged that these may not completely remove
infectivity [19]. Moreover, the recommendations for prion
inactivation are based on rodent-passaged prion isolates, because
measuring infectivity in more relevant species is extremely
expensive and time consuming. The development of transgenic
(Tg) mice expressing a chimeric human/mouse PrP that are highly
susceptible to human prions provided a sensitive model system
[22]. Bioassay of human sporadic (s) CJD prions in these Tg mice
demonstrated that sCJD prions are significantly more resistant to
inactivation, by sodium dodecyl sulfate (SDS) at acidic pH, than
hamster Sc237 prions [23].
We report here on the inactivation of BSE prions and a mouse-
passaged BSE strain, termed 301V. The initial transmission of BSE
prions to wild-type (wt) mice gave rise to multiple strains, one of
which (301V) had a shorter incubation period in mice expressing the
PrP-B polymorphic isoform [24,25]. Even though 301V has been
passagedinmice,ithasbeen assumedbysomeauthorstobeamodel
for the original BSE strain [26]. Due to the major logistical problems
of performing inoculation experiments on cattle, we chose highly
sensitive Tg mouse models expressing either bovine (Bo) PrP or
mouse (Mo) PrP-B. Inactivation of BSE and 301V prions was
accomplished by varying the SDS concentration, the pH and
temperature. Infectivity was measured using Tg mouse lines that are
highly susceptible to either BSE or 301V prions. Bioassays
demonstrated that BSE prions are up to 1,000-fold more resistant
to inactivation than 301V prions while Western immunoblotting
showed that short acidic SDS treatments reduced protease-resistant
PrP
Sc from BSE prions and 301V prions at similar rates. We also
found that BSE prions are 10- and 1,000,000-fold more resistant to
inactivation than sCJD or hamster Sc237 prions, respectively. The
hamster Sc237 strain is identical to the 263K strain used by other
investigators [27,28]. Our studies contend that prion inactivation
proceduresmustbevalidatedbybioassaysagainsttheprionstrainfor
which they are intended to be used.
Materials and Methods
Inocula
Mouse 301V, originally a gift from Dr. H. Fraser, was serially
passaged in B6.I mice expressing the mouse PrP-B polymorphic
isoform [29]. Cattle BSE was from a histopathologically confirmed
Hereford bull, case PG31/90, reported previously [30]. This BSE
sample showed an electrophoretic banding pattern similar to other
BSE samples [31], arguing that it is a ‘‘classical’’ BSE strain. Human
sCJD and hamster Sc237 samples were previously described [23].
Brain homogenates (10% w/v) were prepared in Ca
2+ and
Mg
2+-free phosphate buffered saline (PBS; Invitrogen, Carlsbad,
CA), by either repeated extrusion through successively smaller
needles, via tissue disruption using stainless steel beads in a Mini-
BeadBeater-8 apparatus (BioSPec, Bartlesville, OK), or with a
PowerGen 125 homogenizer, as previously described [23,32,33].
Four-millimeter segments of stainless steel suture wire (Ethicon,
Cornelia, GA) were incubated in brain homogenate as previously
described [23].
Prion inactivation treatments
Acidic SDS treatments were performed by incubating 50-ml
aliquots of brain homogenate with 26 concentration of acidic
SDS, for various durations (30 seconds to 18 h) and temperatures
(65, 121, or 134uC). Samples were then neutralized to stop the
inactivation, and either PrP
Sc levels were detected by Western
blotting or samples were prepared for infectivity bioassay.
PrP
Sc detection by immunoblotting
Treated samples were neutralized and PrP
Sc was determined by
limited proteinase K (PK) digestion and immunoblotting as
described previously [34]. After incubations, 890 ml of cold
neutralization buffer [4% Sarkosyl; 100 mM 4-(2-hydroxyethyl)-
piperazine-1-ethanesulfonic acid (HEPES; pH 7.5); 200 mM
NaCl] was added to each sample. Protease digestion was
performed with 20 mg of PK/ml (Invitrogen, Carlsbad, CA) for
1 h at 37uC. Digestions were terminated by the addition of 10 ml
of 0.1 M phenylmethylsulfonyl fluoride in absolute ethanol
(Roche, Indianapolis, IN). Digested samples were then resus-
pended in a final volume of 200 ml using neutralization buffer
mixed with 46LDS sample buffer (Invitrogen) and 106reducing
agent (Invitrogen). Samples were boiled for 10 min at 100uC prior
to electrophoresis on NuPAGE Bis-Tris 4–12% gels (Invitrogen).
Proteins were transferred onto a PVDF membrane using the iBlot
dry blotting system (Invitrogen).
Material was eluted from wires by incubating in 10% SDS,
20 mM dithiothreitol (DTT) at 100uC for 5 min. The resulting
solution was loaded onto a Minifold slot blot apparatus (Schleicher
& Schuell, Florham Park, NJ) containing a PVDF membrane
presoaked in ethanol.
Membranes were blocked for 30 min with 5% nonfat milk in
TBST (100 mM Tris-HCl, pH 8.0; 150 mM NaCl; 0.5% Tween-
20) and incubated with HRP-conjugated HuM-P monoclonal
antibody diluted to 0.05 mg/ml in TBST for 1 h at room
temperature. Following three 10-min washes in TBST with water
rinses, membranes were developed using an enhanced chemilu-
minescent (ECL) detection system (Amersham, Piscataway, NJ),
followed by exposure to X-ray film. Densitometry was performed
with ImageJ Software (NIH, Bethesda, MD).
Bioassay in transgenic mice
To directly measure infectivity of BSE prions, we performed
bioassays in homozygous Tg mice expressing bovine PrP,
Tg(BoPrP
+/+)4092/Prnp
0/0, described previously [35]. In order
to develop a sensitive and rapid model for the detection of 301V
prions, transgenic mice expressing MoPrP-B at ,4-fold that of wt
mice were generated. The open reading frame of MoPrP-B was
cloned into the Cos.tet vector, then microinjected into Prnp
0/0
zygotes, as previously described [36]. Potential founder mice were
Author Summary
‘‘Mad cow’’ disease, formally known as bovine spongiform
encephalopathy (BSE), belongs to a family of diseases
affecting humans and a number of commercially important
animal species. These diseases are not spread by bacteria or
viruses, but by infectious proteins, termed ‘‘prions.’’ Prions
are known to be very difficult to inactivate, but little is
known about the relative difficulty of inactivation for prions
from different species. Here, we studied the inactivation of
BSE prions and compared it to the inactivation of prions
from humans, mice, and hamsters. We used highly sensitive,
geneticallyengineeredmousemodelstodetectlowlevels of
infectivity. We then quantified the levels of inactivation for a
range of treatments and calculated differences between
prions from different species. We found that naturally
occurring BSE prions can be up to 1 million times more
difficult to inactivatethanthe mostcommonly used hamster
prions. BSE prions were also 1,000 times more difficult to
inactivate than a mouse prion that was thought to be a
surrogate for BSE prions. This study demonstrates that prion
inactivationprocedures need tobevalidated directly against
the prion strains for which they are intended to be used.
Prion Strain Inactivation
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radiolabeled probe complementary to the 39 untranslated region
of the vector [36]. From a founder with a high copy number, we
developed a hemizygous line, denoted Tg(MoPrP-B)2091/Prnp
0/0
mice.
All mice were inoculated intracerebrally with a 30-ml aliquot of
sample. Samples treated with acidic SDS were neutralized by
addition of an equal volume of neutralization buffer, then diluted
10-fold in 5% BSA in PBS, to minimize nonspecific binding to the
vial. For serial dilution of brain homogenate, three independent
replicates of 10 ten-fold serial dilutions of 301V prions were
prepared in Prnp
0/0 brain homogenate, and each inoculated into
groups of four mice. Stainless-steel wires coated in brain
homogenate were implanted as previously described [23]. Mice
were monitored for onset of clinical signs of prion disease, as
described [29,32].
Statistical analysis
While incubation periods are commonly reported as the mean
time from inoculation to onset of disease, analysis of this duration
for samples harboring low infectivity titers requires more rigorous
analysis [23,37]. For the studies reported here, a range of survival
analysis techniques was employed to enable censored data to be
included in the calculations. Median incubation periods were
calculated using the Kaplan-Meier function [38], and 95%
confidence intervals (ci) were determined [39]. When an upper
95% ci could not be calculated by survival analysis techniques, it
was estimated by binomial interpolation, using the times to disease
onset of sick animals. To determine how hazard (disease onset)
varied with time, we developed both semi-parametric Cox [40]
and fully parametric Weibull [41] regression models from survival
data for serially diluted brain homogenate. We also studied how
hazard varied by dilution, as a subjective check of the model, using
a seven-parameter spline. To determine log reduction, the survival
data for positive control and treated samples were compared to the
regression models. When comparing the effect of a given
treatment for two strains, individual Cox regression models were
stratified by strain [42]. Such survival analysis tools have the
advantage of calculating a measure of variability (expressed as
95% ci) for the comparisons.
Specifically, to determine log reduction, we used terms for log
dilution and treatment: ljk(t)=lk(t) exp(bk log dilution+djk
treatment), where the subscripts k and j denote strain and
treatment, respectively. The equivalent log reduction djk=2djk/bk
for the j treatment was then determined separately for each strain.
The equivalent log reduction for a treatment is then the dilution
for which the Cox model predicts the hazard of illness equals the
hazard in the treated animals. We determined 95% ci for dj0,d j1,
and their difference using profile likelihood ratio-based confidence
intervals. All calculations were performed with Stata 9 (Stata
Corp., College Station, TX) and R (R Foundation for Statistical
Computing, Vienna, Austria).
Results
Prion strains have unique electrophoretic characteristics
Western immunoblotting of the four prion strains in this study
revealed distinct electrophoretic profiles. While unglycosylated
PrP
Sc of BSE migrated to 19 kDa (Figure 1A, lane 1), those of
301V, sCJD, and Sc237 had a molecular mass of 21 kDa
(Figure 1A, lanes 2–4). While the host species may influence the
glycoforms ratios, it is interesting to note that mouse 301V and
hamster Sc237 gave similar banding patterns for un-, mono-, and
diglycosylated PrP
Sc.
PrP
Sc of mouse 301V and cattle BSE show similar
resistance to acidic SDS
We tested the resistances of PrP
Sc of cattle BSE and mouse
301V to acidic SDS. Treatment with 4% SDS–1% AcOH for 0.5
to 8 min at 65uC demonstrated a clear time dependence for
Figure 1. Strain characterization and PrP
Sc levels before and
after acidic SDS treatment, by gel electrophoresis. (A) Western
blot of samples after limited digestion with proteinase K. Brain
homogenates (0.5 mg equivalent loaded per lane) were prepared from
a cow with BSE (lane 1), mouse infected with 301V (lane 2), human with
sCJD (lane 3), and hamster infected with Sc237 (lane 4) prions. (B)
Residual PrP
Sc levels of mouse 301V (filled symbols) and cattle BSE
(open symbols) after treatment with 4% SDS–1% AcOH at 65uC, for
0.5 min, 1 min, 2 min, 4 min, or 8 min, as indicated. (C) Residual PrP
Sc
levels of mouse 301V (filled bars) and cattle BSE (open bars) after
treatment with 4% SDS, 1% AcOH, or water for 18 h at 65uC, as
indicated. For (B) and (C), residual PrP
Sc levels were quantified by
densitometry and compared to untreated controls. Values represent
means with error bars representing standard deviations, from at least
three independent measurements.
doi:10.1371/journal.ppat.1000206.g001
Prion Strain Inactivation
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Sc levels for both strains. Although the rates of
PrP
Sc reduction were similar, mouse 301V PrP
Sc was marginally
more resistant to acidic SDS than cattle BSE PrP
Sc (Figure 1B).
Longer treatment durations with acidic SDS reduced the PrP
Sc
signals below detectable levels for both strains, as did treatment
with 4% SDS alone for 18 h (Figure 1C). In comparison,
incubation with either water or 1% AcOH for 18 h at 65uC had
little effect on PrP
Sc levels from either strain (Figure 1C).
Inactivation of prions measured by bioassay
To determine more accurately the differences in inactivation of
prion strains, we turned to bioassays, which are the only direct
method of determining infectivity and have a much larger dynamic
range than Western blots. We previously found that a two-step
treatment protocol, of 4% SDS at 65uC followed by SDS at acidic
pH, was the most effective at inactivating prions [23]. Cattle BSE
and mouse 301V prions were treated with SDS at acidic pH at 65uC
and 134uC for a range of time periods. Additional samples were
incubated at 65uC in either water, 1% acetic acid, or 4% SDS, for
18 h; or autoclaved at 134uC in the absence of acidic SDS. All
experiments were performed in triplicate and inoculated into
independent groups of eight mice (Table 1).
Mouse 301V prions were only partially inactivated by acidic
SDS at 65uC for 30 min: the median incubation period was
significantly extended from 88 d (95% ci: 81, 97) to 305 d, but the
majority of the animals still succumbed to disease. Treatment at
65uC for 18 h further decreased infectivity titers, evidenced by
fewer animals (13%) becoming ill, but failed to inactivate mouse
301V prions beyond the level of detectability. A similar incidence
of sick animals (14%) was seen after autoclaving at a temperature
of 134uC for 15 min in the absence of acidic SDS, but an
equivalent treatment with acidic SDS led to complete survival.
Interestingly, treatment with SDS alone at 65uC for 18 h led to a
significant reduction in mouse 301V infectivity.
Similar to 301V, cattle BSE prions were also resistant to
inactivation. Treatment with acidic SDS at 65uC for 30 min
produced a significant reduction in infectivity, with over 80% of
the mice remaining healthy for the duration of the experiment.
Increasing the treatment time increased the level of inactivation:
after 18 h at 65uC with acidic SDS, no mice succumbed to disease.
Autoclaving at 134uC alone (in the absence of acidic SDS) reduced
BSE infectivity, but complete inactivation required 2 h. In the
presence of acidic SDS, complete inactivation was achieved in
15 min at 134uC, as observed with mouse 301V.
Developing a standard by serial dilution
Due to the different levels of sensitivity of wt and Tg mice to
different prion strains, direct comparison of survival is not an
accurate method. Rather, the log reduction in infectivity for each
strain must be calculated by comparison to serially diluted samples
of the same strain. Tg2091 mice were inoculated with three sets of
independent dilutions of mouse 301V prions; no statistically
significant difference was found between the sets, so the data were
combined for further analyses. As the samples of 301V prions were
titrated from 10
21 to 10
26 dilution of 10% brain homogenate, the
median incubation periods increased from 82 d (95% ci: 69, 90) to
172 d (95% ci: 151, 207). At the 10
27 dilution, only a portion
(,25%) of the animals succumbed to disease. For both the 10
28
and 10
210 dilutions, no animals became ill. However, for the 10
29
dilution, one mouse showed clinical signs at 159 d after
inoculation, and prion disease was confirmed by Western
immunoblotting (Figure 2).
The incubation periods of serially diluted cattle BSE, human
sCJD and hamster Sc237 prions [23,35] were also analyzed using
survival-analysis techniques (Figure S1).
Fitting a mathematical model of the serial dilution data
Two statistical methods were used to model the serially diluted
mouse 301V prions: (i) a semi-parametric Cox model, which
considers relative rate of disease onset, and (ii) the fully parametric
Weibull model, which makes more detailed parametric assump-
tions of how rate of disease varies over time. For each inactivation
treatment, log reductions were calculated by both methods. A plot
of the log reductions determined using the Weibull model against
Table 1. Inactivation of prions in brain homogenates.
Treatment Mouse 301V in Tg2091 mice Cattle BSE in Tg4092 mice
IP (95% ci) Sick (%) IP (95% ci) Sick (%)
Negative control .600 0 .500 0
Positive control 88 (81, 97) 100 272 (256, 277) 100
ddH2O, 18 h, 65uC 95 (95, 99) 100 298 (286, 312) 100
1% AcOH, 18 h, 65uC 102 (99, 106) 100 316 (298, 368) 100
4% SDS, 18 h, 65uC 200 (151, .600) 67 371 (347, 403) 91
4% SDS–1% AcOH, 30 min, 65uC 305 (244, .600) 57 .500 18
4% SDS–1% AcOH, 2 h, 65uC .600 22 .500 5
4% SDS–1% AcOH, 18 h, 65uC .600 13 .500 0
Untreated, 15 min, 134uC .600 14 .500 18
Untreated, 30 min, 134uC .600 0 .500 10
Untreated, 2 h, 134uC .600 0 .500 0
4% SDS–1% AcOH, 15 min, 134uC .600 0 .500 0
4% SDS–1% AcOH, 30 min, 134uC .600 5 .500 0
4% SDS–1% AcOH, 2 h, 134uC .600 0 .500 0
Median incubation period (IP) in days, 95% confidence intervals (ci), and percentage of animals succumbing to prion disease (24 mice per treatment) were calculated by
using Kaplan-Meier analysis.
doi:10.1371/journal.ppat.1000206.t001
Prion Strain Inactivation
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methods produce very similar results (Figure 3), with a correlation
coefficient of 0.99 to the line of identity. We therefore concluded
that the additional assumptions of the Weibull model did not lead
to greater accuracy, and used the Cox model for subsequent
calculations. To test the assumption that the rate of developing
disease was linear over time, we examined how hazard rate varied
across dilutions, using penalized regression splines [43]. The multi-
parameter spline interpolation fitted very closely a two-parameter
linear relationship; thus, we found no evidence of non-linearity in
the observable range, validating our choice of model (Figure S2).
Quantification of prion inactivation
Values of log reduction in infectivity were calculated for each
treatment and strain by comparing survival after treatment with a
positive control, using the appropriate Cox model (Table 2). The
limit of detectability for each set of experiments is a feature of the
infectivity of the positive control and the sensitivity of the
transgenic line. In the inactivation experiments based on 4%
SDS, the maximum log reduction detectable for each of the four
strains was 8.1, 4.0, 7.2, and 7.2 for mouse 301V, cattle BSE,
human sCJD, and hamster Sc237, respectively. When all mice
survive following inoculation with a sample subjected to an
inactivation treatment, the application of survival-analysis tech-
niques enabled the calculation of a lower confidence interval for
the level of inactivation.
Comparing inactivation between strains
The log difference between strains for a given treatment is simply
the arithmetic difference between log reductions, for a given
treatment, for the two strains. However, to determine levels of
significance and confidence intervals for these differences, the
comparisons were stratified using individual Cox models for each
strain. For treatments that led to low levels of prion inactivation
(H2O or AcOH, 18 h, 65uC), mouse 301V prions and cattle BSE
prions had only slightly different inactivation profiles, with a log
difference of 20.4 (95% ci: 21.0, 0.2; p=0.1). At higher levels of
inactivation, mouse 301V prions were significantly less resistant to
inactivation than cattle BSE prions. Treatment with acidic SDS at
65uC for 30 min or 2 h, gave log differences of 1.9 (95% ci: 1.0, 2.8;
p,0.001) and 2.2 (95% ci: 0.3, 3.6; p=0.03) respectively;
autoclaving at 134uC for 15 min in the absence of acidic SDS gave
a log difference of 3.3 (95% ci: 2.0, 4.9; p,0.001). For all other
inactivation treatments one or both the strains had complete survival
of mice and therefore log reduction for the treatments cannot be
calculated. At higher levels of inactivation, mouse 301V prions are
100 to 1000-fold less resistant to inactivation than cattle BSE prions.
Similar treatments on sCJD prions showed them to be
approximately 10-fold easier to inactivate than BSE prions,
however many treatments led to inactivation beyond the limit of
detectability for sCJD prions. With Sc237 prions the 4% SDS
Figure 2. Kaplan-Meier survival curves for serially diluted 301V prions bioassayed in Tg(MoPrP-B)2091/Prnp
0/0 mice. Three
independent 10% brain homogenates were serially diluted 10-fold and each inoculated into 4 mice, which were then monitored for clinical
symptoms of prion disease. No significant differences were observed among the three dilution series and the data were therefore combined.
Incubation period is the number of days from inoculation to manifestation of clinical symptoms. Mice with intercurrent illnesses were censored at the
time of euthanasia.
doi:10.1371/journal.ppat.1000206.g002
Figure 3. Comparison of mathematical models derived from
serial dilution data. Calculations of log reduction upon inactivation
treatment, using the Weibull (abscissa) and Cox (ordinate) models,
produce similar results. Serial dilutions of 301V-infected brain homog-
enate were modeled using the Cox and Weibull regression methods
and log reduction was calculated for each treatment by both methods.
Samples were treated as follows: ddH2O, 65uC, 18 h (a); 1% AcOH, 65uC,
18 h (b); 4% SDS, 65uC, 18 h (c); 4% SDS–1% AcOH at 65uC for 30 min
(d), 2 h (e), and 18 h (f); autoclaved at 134uC for 15 min (g). The
correlation coefficient to the line of identity is 0.99.
doi:10.1371/journal.ppat.1000206.g003
Prion Strain Inactivation
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survival of bioassay mice, and thus an inability to quantify
differences between the strains. We therefore repeated the less
effective 2% SDS–1% AcOH procedures on BSE prions and
compared them with equivalent inactivation treatments on Sc237
and sCJD prions [23] (Table S1). For human sCJD, values for the
log difference to cattle BSE range from non-significant to a log
difference of 2.0 (95% ci: 0.7, 3.9; p,0.001) for acidic 4% SDS at
65uC for 30 min. In general there was about a 1 log difference,
implying that human sCJD prions are ,10-fold less resistant to
inactivation that cattle BSE prions. For Sc237 prions, highly
significant differences against cattle BSE prions were found for
inactivation treatments with acidic 2% SDS at 65uC for 30 min
and autoclaving at 121uC for 15 min in the absence of acidic SDS,
giving log differences of 4.0 (p,0.001) and 5.1 (p,0.001)
respectively. In both cases the upper 95% ci cannot be calculated
due to the limit of the level of detectability. In nearly all other
treatments hamster Sc237 prions were inactivated beyond the level
of detectability, i.e. greater than 8.4 log reduction, even when BSE
infectivity was only reduced by approximately 2 logs, suggesting a
difference of approximately 6 logs. Hamster Sc237 prions were at
least 10,000-fold and in some cases up to 1,000,000-fold, less
resistant to inactivation than cattle BSE prions.
Inactivation of prions bound to stainless steel
Stainless-steel wires soaked in brain homogenates containing
either cattle BSE or mouse 301V prions were subjected to a similar
series of inactivation procedures as the brain homogenates. Wires
were implanted into the brains of the respective Tg mouse lines,
which were then monitored for onset of prion disease (Table 3). To
Table 2. Quantification of log reduction in infectivity, with 95% confidence intervals for various prion strains.
Treatment 301V prions BSE prions sCJD prions Sc237 prions
ddH2O, 18 h, 65uC 0.5 (0.0, 1.0) 0.9 (0.5, 1.2) 2.4 (1.9, 2.9) 0.5 (0.0, 1.1)
1% AcOH, 18 h, 65uC 1.0 (0.5, 1.5) 1.4 (1.0, 1.7) 1.5 (1.2, 1.9) 0.8 (0.4, 1.3)
4% SDS, 18 h, 65uC 4.3 (3.8, 5.0) 1.7 (1.4, 2.1) 3.3 (2.7, 4.0) 2.5 (2.0, 3.1)
4% SDS–1% AcOH, 30 min, 65uC 4.8 (4.2, 5.5) 2.9 (2.4, 3.7) 4.9 (3.9, 6.7) .7.2 (6.4, .7.2)
4% SDS–1% AcOH, 2 h, 65uC 5.8 (5.0, 6.8) 3.6 (2.7, 5.3) 4.2 (3.5, 5.2) .7.2 (6.4, .7.2)
4% SDS–1% AcOH, 18 h, 65uC 6.3 (5.2, 7.8) .4.0 (3.1, .4.0) .7.2 (4.3, .7.2) .7.2 (6.4, .7.2)
Untreated, 15 min, 134uC 6.2 (5.2, 7.8) 2.9 (2.3, 3.7) .7.2 (4.3, .7.2) 7.1 (5.6, .7.2)
Untreated, 30 min, 134uC .8.1 (6.5, .8.1) 3.2 (2.5, 4.3) .7.2 (4.3, .7.2) .7.2 (6.4, .7.2)
Untreated, 2 h, 134uC .8.1 (6.6, .8.1) .4.0 (3.1, .4.0) .7.2 (4.3, .7.2) .7.2 (6.4, .7.2)
4% SDS–1% AcOH, 15 min, 134uC .8.1 (6.8, .8.1) .4.0 (3.1, .4.0) .7.2 (4.3, .7.2) .7.2 (6.4, .7.2)
4% SDS–1% AcOH, 30 min, 134uC 7.4 (5.8, .8.1) .4.0 (3.1, .4.0) .7.2 (4.4, .7.2) .7.2 (6.4, .7.2)
4% SDS–1% AcOH, 2 h, 134uC .8.1 (6.5, .8.1) .4.0 (3.1, .4.0) .7.2 (4.4, .7.2) .7.2 (6.4, .7.2)
doi:10.1371/journal.ppat.1000206.t002
Table 3. Inactivation of prions bound to stainless steel.
Treatment Mouse 301V in Tg2091 mice Cattle BSE in Tg4092 mice
IP (95% ci) Sick (%) IP (95% ci) Sick (%)
Negative control .600 0 .500 0
Positive control 113 (110, 116) 100 350 (336, 357) 100
ddH2O, 18 h, 65uC 116 (109, 124) 100 357 (349, 368) 100
1% AcOH, 18 h, 65uC 117 (111, 125) 100 354 (336, 368) 91
4% SDS, 18 h, 65uC 127 (123, 151) 100 368 (354, 398) 100
4% SDS–1% AcOH, 30 min, 65uC 267 (183, 491) 73 .500 42
4% SDS–1% AcOH, 2 h, 65uC .600 33 .500 26
4% SDS–1% AcOH, 18 h, 65uC 410 (215, .600) 58 .500 4
Untreated, 15 min, 134uC 161 (151, 200) 96 384 (343, 456) 84
Untreated, 30 min, 134uC 438 (232, .600) 57 375 (361, 386) 100
Untreated, 2 h, 134uC .600 14 420 (398, 452) 89
4% SDS–1% AcOH, 15 min, 134uC .600 5 .500 0
4% SDS–1% AcOH, 30 min, 134uC .600 0 .500 0
4% SDS–1% AcOH, 2 h, 134uC .600 0 .500 0
Median incubation period (IP) in days, 95% confidence intervals (ci), and percentage of animals succumbing to prion disease (24 mice per treatment) were calculated by
using Kaplan-Meier analysis.
doi:10.1371/journal.ppat.1000206.t003
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prion-soaked wires were prepared in the same manner, including
the repeated washing steps, then boiled with 10% SDS and
20 mM DTT to elute the bound material. PrP was detected by slot
blot and compared to a serially diluted, prion-infected brain
homogenate. We determined that the amount of PrP bound to
each wire was equivalent to that in ,250 ng of brain tissue. It is
not possible to confirm that all protein was eluted from the wires,
so this must be taken as a minimum value.
Inactivation treatments on prion-coated wires produced only
moderate reductions in the level of infectivity. For example,
autoclaving 301V-coated wires at 134uC for 15 min extended the
median incubation period from 113 d to 161 d, and 96% of
animals developed disease (Table 3). In comparison, the same
procedure on 301V-infected brain homogenate extended the
median incubation period from 88 d to over 600 d, and only 14%
of mice succumbed to disease (Table 1). To remove all detectable
infectivity from wires, acidic SDS treatment at elevated temper-
atures was required. Similar results were found for cattle BSE
prions (Table 3, Table S2).
Discussion
The application of survival analysis techniques to prion
incubation periods provides a more accurate representation of
the data. The distribution of animals succumbing to disease is
rarely symmetrical, and not all animals become sick at low levels of
infectivity. These factors are reflected by reporting median
incubation periods and asymmetric 95% ci, which are by
definition wider than standard deviation or standard error of the
mean. These techniques also allow us to quantify inactivation
using different Tg model systems, in an unbiased way.
We previously demonstrated that human CJD prions were
significantly more resistant to inactivation than hamster Sc237
prions [23]. This differential inactivation of prion strains has also
been observed by others. The phenolic detergent Environ LpH
was shown to inactivate all detectable infectivity of hamster Sc237
prions [44,45], but only modestly reduced infectivity of mouse
RML prions [46].
Rodent-passaged prion strains are widely used in prion
research. While these have been invaluable for understanding
prion biology, great care must be taken in extrapolating any
characteristics of these prions back to the original species and
strain from which they were derived. Recommendations for the
inactivation of human CJD prions were partly based on
experiments on adapted strains of CJD passaged in mice [47],
hamsters [48], and guinea pigs [49]. However, since the sequence
of PrP
Sc is encoded by the host in which the prions were last
passaged, these ‘‘CJD’’ strains are actually mouse, hamster and
guinea pig prions, respectively, which may exhibit different
resistances to inactivation compared to the human CJD prions
from which they were originally derived.
Gel electrophoresiscan be usedto identifythePK-resistant coreof
PrP
Sc, which can differ between strains. This technique was used to
classify human prion strains based on the size of the unglycosylated,
protease-resistant PrP
Sc fragments: type 1 results from cleavage at
residue 82 and has a fragment size of 21 kDa and type 2 results from
cleavage at residue 97 and has a fragment size of 19 kDa [50].
Despite the assumption that 301V is representative of the BSE strain
fromwhichitwasderived,weobserved adifferenceinthesizesofthe
unglycosylated bands between the two strains (Figure 1), which is
consistent with previously published results. A mixture of N-terminal
sequences was obtained from the 301V strain, starting with residue
81[51].Incontrast,BSEwasnotrecognizedbyanantibodydirected
against residues 89–104, suggesting the major cleavage point is
within this region [52]. Furthermore, cattle BSE and mouse 301V
PrP
Sc have different susceptibilities to acidic SDS (Figure 1B,
Tables 1 and 2), suggesting that they are different strains.
We observed differences in the relative effectiveness of
treatments on the two strains, as measured by Western blots and
infectivity bioassay. In all cases, increasing the time and
temperature of acidic SDS treatments led to reduced PrP
Sc levels
and increased inactivation. For acidic SDS treatments of ,8 min,
Western blots of treated mouse 301V and cattle BSE prions
showed similar levels of residual PrP
Sc (Figure 1B). In contrast,
longer acidic SDS treatments demonstrated that cattle BSE prions
were significantly more resistant to inactivation, up to 1,000-fold
compared to mouse 301V prions. PrP
Sc levels of both 301V and
BSE were relatively unchanged by exposure to water or 1%
AcOH for 18 h at 65uC, compared to ,10-fold reduction in
infectivity as detected by bioassay. For both 301V and BSE prions,
incubation with 4% SDS alone for 18 h at 65uC, or with 4%
SDS–1% AcOH for 8 min at 65uC, reduced PrP
Sc to levels
approaching the background signal in Western immunoblots,
which implies a reduction of $2 logs (Figure 1C).
Western blotting is a rapid and convenient way of determining
the level of PrP
Sc, but it is limited by a dynamic range of ,100-
fold. It has long been known that the PrP
Sc level correlates with
infectivity [53], but the precise relationship between the two
remains to be determined. While PrP
Sc was originally defined as
resistance to PK, we have since shown that there are both
protease-resistant (r) and protease-sensitive (s) forms of PrP
Sc [54].
Western blotting only detects rPrP
Sc, while the conformation-
dependent immunoassay [8] and the amyloid seeding assay [55]
are able to detect both rPrP
Sc and sPrP
Sc.
The apparent discrepancies we observed between PrP
Sc level and
infectivity for 301V and BSE prions may be due to several factors.
First, the sPrP
Sc fraction, and its associated infectivity, may be
variable between 301V and BSE. If 301V and BSE have differing
amounts of rPrP
Sc and sPrP
Sc, and at least some infectivity is
associated with sPrP
Sc, then Western blot results would not
necessarily correlate with infectivity. Second, structural differences
between the strains may result in different levels of inactivation.
Presumably, the quaternary structure would be broken down first
when inactivating prions, whereas the tertiary structure would have
to be unfolded to diminish higher levels of infectivity. In such a case,
mouse 301V prions may have an equally stable quaternary structure
but less stable tertiary structure compared to cattle BSE prions.
Cattle or human prions passaged in rodents give rise to rodent
prions. Mouse 301V prions are very resistant to inactivation [56].
Additionally, a human prion strain causing Gerstmann-Stra ¨ussler-
Scheinker disease was passaged in mice; the resulting strain,
termed M1000, was reported to be highly resistant to inactivation
[57]. However, for both 301V and M1000, the relative
susceptibilities to inactivation were not directly compared to their
respective parent strains. We demonstrate here that mouse 301V
and its parent strain, BSE, have different resistances to
inactivation. Therefore, any extrapolation from a rodent-passaged
prion strain to the original parent strain must be interpreted
cautiously. A more suitable model for BSE prions may be BSE
passaged in Tg(BoPrP) mice, which produce PrP
Sc with the BoPrP
sequence as well as with the same electrophoretic mobility and
glycosylation pattern as cattle BSE prions [58]. Infected brains
from this line were recently shown to be suitable for evaluation of
BSE tests [59]. However, these bovine prions are in the milieu of
mouse brain homogenate rather than cattle brain homogenate,
and it remains to be determined whether this has an effect on the
inactivation characteristics.
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human sCJD prions [23], the inactivation of cattle BSE and mouse
301V prions from stainless-steel surfaces is more difficult than
inactivating similar levels of infectivity in brain homogenates.
Stainless-steel wire as a model for surface contamination [60]
provides a useful tool to study prion inactivation from surgical
instruments or machinery used in slaughterhouses. After 4-mm
wires were incubated in 10% brain homogenate, then washed
extensively, we were able to elute PrP equivalent to ,250 ng of
brain tissue from each wire. Other investigators were able to elute
substantially higher PrP levels from wires soaked in brain
homogenate [61], but their wires were not exhaustively washed,
as ours were. Previous studies, using very similar washing
strategies, reported the inability to detect eluted PrP or other
proteins from stainless-steel wires [62]. However, 2 M NaOH used
in those studies may have hydrolyzed many of the proteins,
including PrP.
In conclusion, we have quantified the relative resistance to
inactivation of four prion strains from different species. Cattle BSE
prions appear to be the most resistant strain studied. In
comparison, human sCJD prions are approximately 10-fold less
resistant to inactivation by SDS at neutral or acidic pH, or by heat
alone. Mouse 301V prions are 100- to 1,000-fold less resistant, and
hamster Sc237 prions are up to 1,000,000-fold less resistant to
inactivation. As shown by our findings, prion inactivation based on
rodent-passaged prion strains may not be effective against the
naturally occurring strains for which they were developed.
Supporting Information
Figure S1 Kaplan-Meier survival curves of 10-fold serial
dilutions of (A) cattle BSE prions bioassayed in Tg(BoPrP
+/+)
4092/Prnp
0/0 mice; (B) human sCJD prions bioassayed in
Tg(MHu2M,M165V,E167Q
+/+)22372/Prnp
0/0 mice; (C) hamster
Sc237 prions bioassayed in Tg(SHaPrP
+/+)7/Prnp
0/0 mice. Three
independent serial dilution experiments were performed for each
strain; no significant differences were found between the replicates,
so the data were combined.
Found at: doi:10.1371/journal.ppat.1000206.s001 (0.38 MB TIF)
Figure S2 Variation of hazard rate across serial dilutions for the
301V prion strain. The multi-parameter spline regression (black) is
closely approximated by a linear relationship (gray).
Found at: doi:10.1371/journal.ppat.1000206.s002 (0.07 MB TIF)
Table S1 Inactivation of prion strains in brain homogenates.
Found at: doi:10.1371/journal.ppat.1000206.s003 (0.06 MB
DOC)
Table S2 Inactivation of cattle BSE prions bound to stainless
steel wires.
Found at: doi:10.1371/journal.ppat.1000206.s004 (0.04 MB
DOC)
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